Janus Kinases in Leukemia

Näytä kaikki kuvailutiedot



Pysyväisosoite

http://hdl.handle.net/10138/328842

Lähdeviite

Raivola , J , Haikarainen , T , Abraham , B G & Silvennoinen , O 2021 , ' Janus Kinases in Leukemia ' , Cancers , vol. 13 , no. 4 , 800 . https://doi.org/10.3390/cancers13040800

Julkaisun nimi: Janus Kinases in Leukemia
Tekijä: Raivola, Juuli; Haikarainen, Teemu; Abraham, Bobin George; Silvennoinen, Olli
Tekijän organisaatio: Helsinki Institute of Life Science HiLIFE
Institute of Biotechnology
University Management
University of Helsinki
Päiväys: 2021-02
Kieli: eng
Sivumäärä: 20
Kuuluu julkaisusarjaan: Cancers
ISSN: 2072-6694
DOI-tunniste: https://doi.org/10.3390/cancers13040800
URI: http://hdl.handle.net/10138/328842
Tiivistelmä: Simple Summary Janus kinase/signal transducers and activators of transcription (JAK/STAT) pathway is a crucial cell signaling pathway that drives the development, differentiation, and function of immune cells and has an important role in blood cell formation. Mutations targeting this pathway can lead to overproduction of these cell types, giving rise to various hematological diseases. This review summarizes pathogenic JAK/STAT activation mechanisms and links known mutations and translocations to different leukemia. In addition, the review discusses the current therapeutic approaches used to inhibit constitutive, cytokine-independent activation of the pathway and the prospects of developing more specific potent JAK inhibitors. Janus kinases (JAKs) transduce signals from dozens of extracellular cytokines and function as critical regulators of cell growth, differentiation, gene expression, and immune responses. Deregulation of JAK/STAT signaling is a central component in several human diseases including various types of leukemia and other malignancies and autoimmune diseases. Different types of leukemia harbor genomic aberrations in all four JAKs (JAK1, JAK2, JAK3, and TYK2), most of which are activating somatic mutations and less frequently translocations resulting in constitutively active JAK fusion proteins. JAKs have become important therapeutic targets and currently, six JAK inhibitors have been approved by the FDA for the treatment of both autoimmune diseases and hematological malignancies. However, the efficacy of the current drugs is not optimal and the full potential of JAK modulators in leukemia is yet to be harnessed. This review discusses the deregulation of JAK-STAT signaling that underlie the pathogenesis of leukemia, i.e., mutations and other mechanisms causing hyperactive cytokine signaling, as well as JAK inhibitors used in clinic and under clinical development.
Avainsanat: leukemia
Janus kinases
kinase inhibitor
3122 Cancers
Vertaisarvioitu: Kyllä
Tekijänoikeustiedot: cc_by
Pääsyrajoitteet: openAccess
Rinnakkaistallennettu versio: publishedVersion


Tiedostot

Latausmäärä yhteensä: Ladataan...

Tiedosto(t) Koko Formaatti Näytä
cancers_13_00800_v2.pdf 1.957MB PDF Avaa tiedosto

Viite kuuluu kokoelmiin:

Näytä kaikki kuvailutiedot